What are the outcomes associated with lamivudine (3TC) in the treatment of hepatitis B (HBV) (Hep B)?

Updated: Jun 08, 2021
  • Author: Nikolaos T Pyrsopoulos, MD, PhD, MBA, FACP, AGAF; Chief Editor: BS Anand, MD  more...
  • Print

Therapy with 3TC has been associated with a 4-log reduction of the viral load. [64, 80, 81, 82] Treatment (100 mg/day) has also been associated with the following:

  • 16-18% seroconversion rate from HBeAg to anti-HBe

  • 30-33% rate of HBeAg loss

  • 40-50% normalization of the value of the aminotransferases

  • 1-2% HBsAg seroconversion rate

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!